Literature DB >> 2166801

Modulation of the potency and efficacy of mu-mediated antinociception by delta agonists in the mouse.

J N Qi1, H I Mosberg, F Porreca.   

Abstract

Previous reports have shown that [Leu5]enkephalin or [Met5] enkephalin, endogenous delta receptor agonists, or synthetic analogues of these substances, can respectively produce a positive (i.e., increase) or negative (i.e., decrease) modulation of the antinociceptive potency of mu agonists such as morphine; such modulation is believed to be the result of interactions between delta and mu receptors. In spite of these studies showing modulation of mu agonist potency, it is unclear whether delta agonists can similarly modulate the antinociceptive efficacy of mu agonists. This question was addressed by using several levels of nociceptive stimulus intensity in mice. As the nociceptive stimulus intensity increased, the i.c.v. morphine dose-response line was shown to be displaced progressively to the right with decreasing maximal effect (i.e., decreased efficacy) a pattern typical of partial agonists. In contrast, the antinociceptive potency and efficacy of i.c.v. etorphine was unaffected by increasing the stimulus intensity, suggesting that this compound has higher efficacy than morphine in this nociceptive assay. Coadministration of delta opioid agonists produced leftward ([D-Pen2, D-Pen5] enkephalin) or rightward ([Met5]enkephalin) displacement of the morphine dose-response line (i.e., changes in potency). When the delta agonists were coadministered with morphine under conditions of high stimulus intensity, the maximal antinociceptive effects of i.c.v. morphine were increased or decreased from studies with morphine alone (i.e., change in efficacy). Both changes in potency and efficacy produced by the delta agonists, but not the direct antinociceptive effects of morphine, were blocked by the delta antagonist, ICI 174,864, suggesting that modulation occurred via the delta receptor.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2166801

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  22 in total

1.  Mu and Delta opioid receptors activate the same G proteins in human neuroblastoma SH-SY5Y cells.

Authors:  A Alt; M J Clark; J H Woods; J R Traynor
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

2.  How to design an opioid drug that causes reduced tolerance and dependence.

Authors:  Amy Chang Berger; Jennifer L Whistler
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

3.  Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.

Authors:  Henry I Mosberg; Larisa Yeomans; Aubrie A Harland; Aaron M Bender; Katarzyna Sobczyk-Kojiro; Jessica P Anand; Mary J Clark; Emily M Jutkiewicz; John R Traynor
Journal:  J Med Chem       Date:  2013-02-27       Impact factor: 7.446

4.  Plasma membrane cholesterol level and agonist-induced internalization of δ-opioid receptors; colocalization study with intracellular membrane markers of Rab family.

Authors:  Jana Brejchova; Miroslava Vosahlikova; Lenka Roubalova; Marco Parenti; Mario Mauri; Oleksandr Chernyavskiy; Petr Svoboda
Journal:  J Bioenerg Biomembr       Date:  2016-07-13       Impact factor: 2.945

5.  Effects of the delta opioid against BW373U86 in pigeons trained to discriminate fentanyl, bremazocine and water in a three-choice drug discrimination procedure.

Authors:  S S Negus; D Morgan; C D Cook; M J Picker
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

6.  Entanglement between thermoregulation and nociception in the rat: the case of morphine.

Authors:  Nabil El Bitar; Bernard Pollin; Elias Karroum; Ivanne Pincedé; Daniel Le Bars
Journal:  J Neurophysiol       Date:  2016-09-07       Impact factor: 2.714

7.  Development of potent μ and δ opioid agonists with high lipophilicity.

Authors:  Yeon Sun Lee; Vinod Kulkarani; Scott M Cowell; Shou-wu Ma; Peg Davis; Katherine E Hanlon; Todd W Vanderah; Josephine Lai; Frank Porreca; Ruben Vardanyan; Victor J Hruby
Journal:  J Med Chem       Date:  2010-12-03       Impact factor: 7.446

8.  Enkephalin analogues with N-phenyl-N-(piperidin-2-ylmethyl)propionamide derivatives: Synthesis and biological evaluations.

Authors:  Srinivas Deekonda; Jacob Cole; Sydney Sunna; David Rankin; Tally M Largent-Milnes; Peg Davis; Neemah M BassiriRad; Josephine Lai; Todd W Vanderah; Frank Porecca; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2015-11-03       Impact factor: 2.823

9.  Variation in tolerance to the antinociceptive, hormonal and thermal effects of morphine after a 5-day pre-treatment of male rats with increasing doses of morphine.

Authors:  P T Männistö; S A Borisenko; P Rauhala; P Tuomainen; R K Tuominen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-02       Impact factor: 3.000

10.  Development of novel enkephalin analogues that have enhanced opioid activities at both mu and delta opioid receptors.

Authors:  Yeon Sun Lee; Ravil Petrov; Chad K Park; Shou-wu Ma; Peg Davis; Josephine Lai; Frank Porreca; Ruben Vardanyan; Victor J Hruby
Journal:  J Med Chem       Date:  2007-10-10       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.